L. Bertilsson

High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands.

T Ishizaki, T Kobayakawa, L. Bertilsson, 1999, Pharmacogenetics.

Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.

M Ingelman-Sundberg, M. Ingelman-Sundberg, L. Bertilsson, 1996, Pharmacogenetics.

DISASSOCIATION BETWEEN DEBRISOQUINE HYDROXYLATION PHENOTYPE AND GENOTYPE AMONG CHINESE

M. Ingelman-Sundberg, L. Bertilsson, I. Johansson, 1989, The Lancet.

Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19.

L. Bertilsson, M. Dahl, G. Tybring, 1995, British journal of clinical pharmacology.

Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine.

M. Ingelman-Sundberg, L. Bertilsson, I. Johansson, 1999, Pharmacogenetics.

Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism

P. Bech, L. Bertilsson, S. Otton, 2004, European Journal of Clinical Pharmacology.

A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity.

M. Ingelman-Sundberg, L. Bertilsson, C. Masimirembwa, 2003, British journal of clinical pharmacology.

The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients.

L. Bertilsson, K. Otani, S. Kaneko, 1997, Journal of clinical psychopharmacology.

Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.

C. Alm, L. Bertilsson, M. Dahl, 2000, Therapeutic drug monitoring.